Bifogade filer
Kurs & Likviditet
Prenumeration
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
October – December 2023
• Net sales: TSEK 596 (5,346).
• Other operating revenues: TSEK 875 (579).
• Profit from financial items: TSEK -6,360 (-11,942).
• Earnings per share: SEK -0.32 (-0.60).
January – December 2023
• Net sales: TSEK 5,544 (26,699).
• Other operating revenues: TSEK 1,464 (14,548).
• Profit from financial items: TSEK -35,665 (-6,157).
• Earnings per share: SEK -1.80 (-0.31).
• Cash and cash equivalents: TSEK 101,440 (131,777).
Events during quarter 4
• Spark Therapeutics terminates collaboration agreement for the epilepsy project CG01 with CombiGene.
• CombiGene and Zyneyro choose initial indication in the COZY01 pain project.
• CombiGene chooses Charles River as preclinical toxicology partner for COZY01 pain project.
• Eurostars contributes SEK 8,7 million to the financing of the COZY01 pain project.
Events after the end of the year
• CombiGene regains the global rights to the epilepsy project CG01.
• CombiGene discontinues the preclinical development of the lipodystrophy project CGT2.